Education
About Us
Working with TipRanks
Follow Us
Austar Lifesciences Ltd. (HK:6118)
:6118
RESEARCH TOOLSreports
6118 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$0.45 - HK$1.10
Previous CloseN/A
Volume4.00K
Average Volume (3M)111.93K
Market Cap
HK$358.81M
Enterprise ValueHK$2.23B
Total Cash (Recent Filing)HK$167.81M
Total Debt (Recent Filing)¥401.95M
Price to Earnings (P/E)20.0
Beta0.30
Next Earnings
Sep 02, 2025EPS EstimateN/A
Last Dividend Ex-Date
May 19, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding512,582,030
10 Day Avg. Volume240,000
30 Day Avg. Volume111,933
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)1.02
Price to Sales (P/S)0.00
P/FCF Ratio-5.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Austar Lifesciences Ltd. News
PremiumCompany Announcements
Austar Lifesciences Secures Unanimous Approval at AGM
PremiumCompany Announcements
Austar Lifesciences Ltd. Announces 2025 Annual General Meeting
PremiumCompany Announcements
Austar Lifesciences Reports Positive Turnaround in 2024 Annual Results
PremiumCompany Announcements
Austar Lifesciences to Review Annual Results and Dividend Proposal
PremiumCompany Announcements
Austar Lifesciences Announces Positive Profit Outlook for 2024
PremiumCompany Announcements
Austar Lifesciences Acquires Full Control of Target Company
PremiumCompany Announcements
Austar Lifesciences Ends Relocation Agreement
PremiumCompany Announcements
Austar Lifesciences Returns to Profitability in H1 20246118 FAQ
What was Austar Lifesciences Ltd.’s price range in the past 12 months?
Austar Lifesciences Ltd. lowest stock price was HK$0.45 and its highest was HK$1.10 in the past 12 months.
What is Austar Lifesciences Ltd.’s market cap?
Austar Lifesciences Ltd.’s market cap is HK$358.81M.
When is Austar Lifesciences Ltd.’s upcoming earnings report date?
Austar Lifesciences Ltd.’s upcoming earnings report date is Sep 02, 2025 which is in 81 days.
How were Austar Lifesciences Ltd.’s earnings last quarter?
Austar Lifesciences Ltd. released its earnings results on Mar 26, 2025. The company reported HK$0.022 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.022.
Is Austar Lifesciences Ltd. overvalued?
According to Wall Street analysts Austar Lifesciences Ltd.’s price is currently Overvalued.
Does Austar Lifesciences Ltd. pay dividends?
Austar Lifesciences Ltd. pays a Notavailable dividend of HK$0.05 which represents an annual dividend yield of N/A. See more information on Austar Lifesciences Ltd. dividends here
What is Austar Lifesciences Ltd.’s EPS estimate?
Austar Lifesciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Austar Lifesciences Ltd. have?
Austar Lifesciences Ltd. has 512,582,030 shares outstanding.
What happened to Austar Lifesciences Ltd.’s price movement after its last earnings report?
Austar Lifesciences Ltd. reported an EPS of HK$0.022 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.529%.
Which hedge fund is a major shareholder of Austar Lifesciences Ltd.?
Currently, no hedge funds are holding shares in HK:6118
Austar Lifesciences Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.82%
12-Months-Change
Fundamentals
Return on Equity
2.06%
Trailing 12-Months
Asset Growth
-6.71%
Trailing 12-Months
Company Description
Austar Lifesciences Ltd.
Austar Lifesciences Ltd. (6118) is a leading provider of integrated engineering solutions, equipment, and services for the pharmaceutical and life sciences industries. The company specializes in the design and implementation of cleanrooms, containment systems, and other critical environments essential for the production and development of pharmaceutical products. Austar's offerings cater to various sectors, including biotechnology, healthcare, and manufacturing, providing essential infrastructure and support to ensure compliance with industry standards and regulations.
Technical Analysis
Viva Biotech Holdings
―
Ascletis Pharma, Inc.
―
3SBio
―
Shanghai Fosun Pharmaceutical (Group) Co
―
Wuxi Biologics (Cayman)
―